Daniel Joseph OConnell - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
President and CEO, Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jul 6, 2021
Transactions value $
-$4
Form type
4
Date filed
7/8/2021, 06:16 PM
Previous filing
Jun 30, 2021
Next filing
Dec 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Conversion of derivative security +123 +8.67% 1.54K Jul 6, 2021 Direct F1
transaction ABOS Common Stock Exercise of in-the-money or at-the-money derivative security $156 +35 +2.27% $4.47 1.58K Jul 6, 2021 Direct
transaction ABOS Common Stock Tax liability -$160 -10 -0.63% $16.00 1.57K Jul 6, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Series A Preferred Stock Conversion of derivative security -123 -100% 0 Jul 6, 2021 Common Stock 123 Direct F1
transaction ABOS Warrant (Right to Buy) Options Exercise $0 -35 -100% $0.00* 0 Jul 6, 2021 Common Stock 35 $4.47 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 On July 6, 2021, the reporting person exercised a warrant to purchase 35 shares of ABOS common stock for $4.47 a share. The reporting person paid the exercise price on a cashless basis, resulting in ABOS's withholding of 10 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 25 shares.